Certain biomarkers, including those found by TIDE, are more accurate at predicting the fate of melanoma patients treated with first-line anti-PD-1 or anti-CTLA-4 antibodies than other biomarkers, such as PD-L1 levels and tumor mutation burden (TMB)23. The gene discussed is CTLA4; the disease is neoplasm.